AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21197536 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan in addition to conventional heart failure therapy
Number of subjects: 24
Study 21197536 — intervention group
Group type: COMPARATOR
Intervention: Conventional heart failure therapy (control group)
Number of subjects: 24
Study 21197536 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan in addition to conventional therapy
Number of subjects: 24
Study 19491859 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsalazide 3.3 g (1.1 g tablet, twice daily for 8 weeks)
Number of subjects: 249
Study 19491859 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 8 weeks)
Number of subjects: 249
Study 18020939 — intervention group
Group type: EXPERIMENTAL
Intervention: Acculturation
Number of subjects: 526
Study 18020939 — intervention group
Group type: COMPARATOR
Intervention: Perceived neighborhood safety/aesthetics
Number of subjects: 526
Study 16157113 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vaginal misoprostol (600 microg x 1, then 400 microg every 4 hours x 5)
Number of subjects: 38
Study 16157113 — intervention group
Group type: COMPARATOR
Intervention: Concentrated intravenous oxytocin plus low-dose vaginal misoprostol (oxytocin 277-1667 mU/min plus 400 microg x 1, then 200 microg every 6 hours x 2, then 100 microg x 1)
Number of subjects: 38
Study 16157113 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vaginal misoprostol
Number of subjects: 38
Study 16157113 — intervention group
Group type: COMPARATOR
Intervention: Concentrated intravenous oxytocin plus low-dose vaginal misoprostol
Number of subjects: 38
Study 12496952 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino-acid drink containing tryptophan
Number of subjects: 18
Study 12496952 — intervention group
Group type: COMPARATOR
Intervention: Amino-acid drink without tryptophan (Control)
Number of subjects: 18
Study 10071506 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients with osteopenia
Number of subjects: 72
Study 10071506 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients with osteoporosis
Number of subjects: 72
Study 10071506 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients with normal density
Number of subjects: 72
Study 10071506 — intervention group
Group type: COMPARATOR
Intervention: Control group (osteoarthritis patients)
Number of subjects: 72
Study 7729398 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective mask
Number of subjects: 160
Study 7729398 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective jacket
Number of subjects: 160
Study 7729398 — intervention group
Group type: COMPARATOR
Intervention: No RPDs
Number of subjects: 160
Study 7729398 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful evacuation with RPDs
Number of subjects: 160
Study 2118322 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg daily, orally
Number of subjects: 86
Study 2118322 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin 250 mg four times a day, orally
Number of subjects: 86
Study 6112447 — intervention group
Group type: EXPERIMENTAL
Intervention: UK‐37 248 (200 mg)
Number of subjects: 0
Study 6112447 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 30115415 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing education
Number of subjects: 357
Study 30115415 — intervention group
Group type: COMPARATOR
Intervention: Control group with reminder report
Number of subjects: 357
Study 30115415 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 357
Study 27630092 — intervention group
Group type: EXPERIMENTAL
Intervention: Four implants
Number of subjects: 50
Study 27630092 — intervention group
Group type: COMPARATOR
Intervention: Six implants
Number of subjects: 50
Study 24793076 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbopelvic manipulation (grade V)
Number of subjects: 75
Study 24793076 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbopelvic manipulation positioning (no thrust)
Number of subjects: 75
Study 24793076 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade IV patellar mobilisation
Number of subjects: 75
Study 24793076 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade I patellar mobilisation
Number of subjects: 75
Study 24793076 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 75
Study 23078148 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol (100/10 μg b.i.d.)
Number of subjects: 0
Study 20381580 — intervention group
Group type: EXPERIMENTAL
Intervention: Provoked without reward for aggression
Number of subjects: 0
Study 20381580 — intervention group
Group type: COMPARATOR
Intervention: Provoked with reward for aggression
Number of subjects: 0
Study 20381580 — intervention group
Group type: COMPARATOR
Intervention: Not provoked with reward for aggression
Number of subjects: 0
Study 20381580 — intervention group
Group type: COMPARATOR
Intervention: Not provoked without reward for aggression
Number of subjects: 0
Study 18537467 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (VA) at acupuncture point Large Intestine 4 (Hegu)
Number of subjects: 20
Study 18537467 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (VA)
Number of subjects: 20
Study 18537467 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture (PA) at a sham point
Number of subjects: 20
Study 16174840 — intervention group
Group type: EXPERIMENTAL
Intervention: Number Needed to Treat (NNT)
Number of subjects: 0
Study 16174840 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute risk reduction
Number of subjects: 0
Study 16174840 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative measures of benefits
Number of subjects: 0
Study 16174840 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute measures of therapeutic yield
Number of subjects: 0
Study 11908533 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistently negative feedback
Number of subjects: 0
Study 11908533 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing feedback from positive to negative
Number of subjects: 0
Study 10084489 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (left chest tube inserted from the midline, subxyphoid)
Number of subjects: 30
Study 10084489 — intervention group
Group type: COMPARATOR
Intervention: Group B (tube placed in the sixth intercostal space at the anterior axillary line)
Number of subjects: 30
Study 10084489 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 30
Study 10084489 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 30
Study 7555622 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ), titrated to 4-12 micrograms/ml
Number of subjects: 82
Study 7555622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 2208421 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of Scutellaria compound
Number of subjects: 60
Study 2208421 — intervention group
Group type: COMPARATOR
Intervention: Intravenous piperacillin sodium
Number of subjects: 60
Study 6109147 — intervention group
Group type: EXPERIMENTAL
Intervention: Real ECT
Number of subjects: 70
Study 6109147 — intervention group
Group type: COMPARATOR
Intervention: Simulated ECT
Number of subjects: 70
Study 30081009 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillomandibular advancement (MMA)
Number of subjects: 30
Study 28954501 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-week early cardiac rehabilitation (CR) exercise training
Number of subjects: 65
Study 25713429 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial telephone counseling (PTC)
Number of subjects: 204
Study 25713429 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 204
Study 24517055 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Zhuanggu Quhan Decoction + WM placebos (Group A)
Number of subjects: 96
Study 24517055 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Zhuanggu Qinghua Decoction + WM placebos (Group B)
Number of subjects: 96
Study 24517055 — intervention group
Group type: COMPARATOR
Intervention: SASP + TCM placebos (Group C)
Number of subjects: 96
Study 24517055 — intervention group
Group type: COMPARATOR
Intervention: SASP + TCM placebos (Group D)
Number of subjects: 96
Study 24517055 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM treatment group (combined A and B)
Number of subjects: 96
Study 21639808 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib (960 mg orally twice daily)
Number of subjects: 675
Study 21639808 — intervention group
Group type: COMPARATOR
Intervention: dacarbazine (1000 mg/m² intravenously every 3 weeks)
Number of subjects: 675
Study 21639808 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib
Number of subjects: 675
Study 21639808 — intervention group
Group type: COMPARATOR
Intervention: dacarbazine
Number of subjects: 675
Study 19853906 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 564
Study 19853906 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 564
Study 19853906 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 2.4 mg
Number of subjects: 564
Study 19853906 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 564
Study 19853906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study 19853906 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg
Number of subjects: 564
Study 19853906 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (all doses)
Number of subjects: 564
Study 19853906 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8-3.0 mg
Number of subjects: 564
Study 16419071 — intervention group
Group type: COMPARATOR
Intervention: VAD alone
Number of subjects: 94
Study 16419071 — intervention group
Group type: EXPERIMENTAL
Intervention: valspodar/VAD
Number of subjects: 94
Study 12727150 — intervention group
Group type: EXPERIMENTAL
Intervention: Early revascularization <18 hours since onset of shock
Number of subjects: 865
Study 12727150 — intervention group
Group type: COMPARATOR
Intervention: Late or no revascularization
Number of subjects: 865
Study 10965733 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1% (10 mg/ml)
Number of subjects: 73
Study 10965733 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2% (20 mg/ml)
Number of subjects: 73
Study 8911979 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride at a daily dose of 1-6 mg for 3 months in NIDDM patients with kidney disease
Number of subjects: 42
Study 8911979 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride in patients with liver disease
Number of subjects: 42
Study 1507042 — intervention group
Group type: COMPARATOR
Intervention: Root planed only (Group 2)
Number of subjects: 18
Study 1507042 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treated only using 1.25 W of energy (Group 3)
Number of subjects: 18
Study 1507042 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treated only using 1.50 W of energy (Group 4)
Number of subjects: 18
Study 1507042 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treated with 1.25 W of energy followed by root planing (Group 5)
Number of subjects: 18
Study 1507042 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treated with 1.50 W of energy followed by root planing (Group 6)
Number of subjects: 18
Study 6509875 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride injection alone
Number of subjects: 412
Study 6509875 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin 10 units/ml in 0.9% sodium chloride injection
Number of subjects: 412
Study 6509875 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin 100 units/ml in 0.9% sodium chloride injection
Number of subjects: 412
Study 31385180 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL-MPA-S
Number of subjects: 15008
Study 31385180 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL-TAC-S
Number of subjects: 15008
Study 31385180 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL-CSA-S
Number of subjects: 15008
Study 31385180 — intervention group
Group type: COMPARATOR
Intervention: TAC-MPA-S
Number of subjects: 15008
Study 28371815 — intervention group
Group type: EXPERIMENTAL
Intervention: FG-4592 low-dose (1.1-1.75 mg/kg)
Number of subjects: 178
Study 28371815 — intervention group
Group type: EXPERIMENTAL
Intervention: FG-4592 high-dose (1.50-2.25 mg/kg)
Number of subjects: 178
Study 28371815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 28371815 — intervention group
Group type: EXPERIMENTAL
Intervention: FG-4592 low-dose (1.1-1.8 mg/kg)
Number of subjects: 178
Study 28371815 — intervention group
Group type: EXPERIMENTAL
Intervention: FG-4592 medium-dose (1.5-2.3 mg/kg)
Number of subjects: 178
Study 28371815 — intervention group
Group type: EXPERIMENTAL
Intervention: FG-4592 high-dose (1.7-2.3 mg/kg)
Number of subjects: 178
Study 28371815 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 178
Study 28371815 — intervention group
Group type: EXPERIMENTAL
Intervention: FG-4592 (all doses)
Number of subjects: 178
Study 28371815 — intervention group
Group type: EXPERIMENTAL
Intervention: FG-4592 high-dose
Number of subjects: 178
Study 25732264 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus pemetrexed (GP)
Number of subjects: 94
Study 25732264 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (GC)
Number of subjects: 94
Study 23512113 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-obturator polypropylene mesh
Number of subjects: 147
Study 23512113 — intervention group
Group type: COMPARATOR
Intervention: Anterior colporrhaphy
Number of subjects: 147
Study 23512113 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 147
Study 21511749 — intervention group
Group type: EXPERIMENTAL
Intervention: ICRU point doses in Group A (n=50)
Number of subjects: 150
Study 21511749 — intervention group
Group type: COMPARATOR
Intervention: Statistical validation in Group B (n=100)
Number of subjects: 150
Study 20112486 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 0
Study 20112486 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 0
Study 16918716 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (3 g daily)
Number of subjects: 83
Study 16918716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 14639479 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training in addition to aerobic training (n=9); trained on 12 resistance machines, performing three sets of 8-12 repetitions at 32-64% of their one-repetition maximum (1-RM) lifts
Number of subjects: 17
Study 14639479 — intervention group
Group type: COMPARATOR
Intervention: Control/aerobic training (n=8)
Number of subjects: 17
Study 11605012 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (including anthracycline and non-anthracycline based regimens)
Number of subjects: 0
Study 11605012 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 11605012 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 0
Study 11605012 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin and cyclophosphamide (AC)
Number of subjects: 0
Study 9469687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (Atrovent) nebulizer solution with BAC and EDTA
Number of subjects: 0
Study 9469687 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol nebulizer solution with BAC
Number of subjects: 0
Study 9469687 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA in nebulizer solutions
Number of subjects: 0
Study 9469687 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free bronchodilator nebulizer solutions
Number of subjects: 0
Study 7927550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol estimation from cord artery, cord vein at birth and from peripheral vein at 6 h of age.
Number of subjects: 60
Study 7927550 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal venous blood cortisol estimation at birth.
Number of subjects: 60
Study 7927550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood pH measurement at birth.
Number of subjects: 60
Study 2556910 — intervention group
Group type: EXPERIMENTAL
Intervention: very-high-fiber (VHF) cereal
Number of subjects: 14
Study 2556910 — intervention group
Group type: COMPARATOR
Intervention: very-low-fiber (VLF) cereal
Number of subjects: 14
Study 2556910 — intervention group
Group type: EXPERIMENTAL
Intervention: high-fiber cereals
Number of subjects: 14
Study 2556910 — intervention group
Group type: EXPERIMENTAL
Intervention: higher-fiber cereals
Number of subjects: 14
Study 125068 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 1.5% aqueous solution of 6-aminonicotinamide for four weeks
Number of subjects: 34
Study 125068 — intervention group
Group type: COMPARATOR
Intervention: Solvent alone (control)
Number of subjects: 34
Study 125068 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied thionicotinamide
Number of subjects: 34
Study 30676219 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal exercise program performed barefoot
Number of subjects: 3
Study 30676219 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal exercise program performed shod
Number of subjects: 3
Study 30676219 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical exercise)
Number of subjects: 3
Study 28987873 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with knee osteoarthritis at 5 years after anterior cruciate ligament reconstruction
Number of subjects: 19
Study 28987873 — intervention group
Group type: COMPARATOR
Intervention: Patients without knee osteoarthritis at 5 years after anterior cruciate ligament reconstruction
Number of subjects: 19
Study 24895097 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lowering of LDL-cholesterol and blood pressure
Number of subjects: 100
Study 24895097 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy indicated by current guidelines
Number of subjects: 100
Study 23937923 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg intravenous dexamethasone intraoperatively
Number of subjects: 120
Study 23937923 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour postoperative dose of 10mg intravenous dexamethasone
Number of subjects: 120
Study 23937923 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 120
Study 21504256 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR system call 7 days before the procedure
Number of subjects: 3610
Study 21504256 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR system call 3 days before the procedure
Number of subjects: 3610
Study 21504256 — intervention group
Group type: COMPARATOR
Intervention: Nurse phone call 7 days before the procedure
Number of subjects: 3610
Study 18650033 — intervention group
Group type: EXPERIMENTAL
Intervention: Open label sustained-release bupropion (300 mg/day) with gain-framed messages
Number of subjects: 207
Study 18650033 — intervention group
Group type: EXPERIMENTAL
Intervention: Open label sustained-release bupropion (300 mg/day) with loss-framed messages
Number of subjects: 207
Study 18650033 — intervention group
Group type: COMPARATOR
Intervention: Expired CO
Number of subjects: 207
Study 18650033 — intervention group
Group type: COMPARATOR
Intervention: Plasma cotinine
Number of subjects: 207
Study 16858180 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (intra-arterial, intraoperative bolus of 3000 ng, plus intravenous infusion of 0.5-2.0 ng/kg/min for 6 hours/day for 4-7 days following surgery)
Number of subjects: 300
Study 16858180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 16858180 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 300
Study 12460133 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-session cognitive behavioral treatment (CBT) with motivational enhancement therapy (MET) and case management (CM) components
Number of subjects: 450
Study 12460133 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-session MET intervention
Number of subjects: 450
Study 12460133 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control (DTC)
Number of subjects: 450
Study 10466460 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 0
Study 10466460 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 10466460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10466460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure
Number of subjects: 0
Study 10466460 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean blood pressure
Number of subjects: 0
Study 8576309 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic HEV peptides (EH174 from ORF-1, EH286 from ORF-2, EH362 from ORF-3) used in peptide-based ELISA test kits.
Number of subjects: 0
Study 8576309 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide-based ELISA test kits using a set of 3 synthetic HEV peptides as coating antigens.
Number of subjects: 0
Study 8576309 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroepidemiological survey.
Number of subjects: 0
Study 2024858 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (high-dose steroid therapy plus cyclophosphamide therapy for 8 weeks)
Number of subjects: 86
Study 2024858 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis treatment (12 plasmapheresis procedures during the first 4 weeks)
Number of subjects: 86
Study 7440855 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide aerosol
Number of subjects: 73
Study 7440855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 6724070 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir cream
Number of subjects: 52
Study 6724070 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 52
Study 6724070 — intervention group
Group type: COMPARATOR
Intervention: Liquid nitrogen
Number of subjects: 52
Study 6724070 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nitrogen (subsequent treatment)
Number of subjects: 52